hVIVO (LON:HVO) Posts Earnings Results

hVIVO (LON:HVO) issued its earnings results on Tuesday. The company reported GBX (0.82) EPS for the quarter, Digital Look Earnings reports. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%.

hVIVO Price Performance

LON:HVO traded down GBX 0.30 on Tuesday, reaching GBX 6.10. The stock had a trading volume of 4,701,018 shares, compared to its average volume of 2,553,296. The company has a market capitalization of £41.99 million, a P/E ratio of -7.01 and a beta of 1.69. hVIVO has a 1-year low of GBX 4.30 and a 1-year high of GBX 11. The company has a quick ratio of 1.16, a current ratio of 1.63 and a debt-to-equity ratio of 38.75. The stock has a fifty day moving average price of GBX 6.81 and a 200-day moving average price of GBX 7.41.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.